Zobrazeno 1 - 10
of 19
pro vyhledávání: ''
Autor:
Cory Abate-Shen, Amir Lankarani, Matteo Di Bernardo, Michael M. Shen, Rivka L. Shoulson, Soonbum Park, Lijie Rong, Tomasz Owczarek, Talal Syed, Hikmat Al-Ahmadie, David B. Solit, James M. McKiernan, Chee-Wai Chua, Prithi Chakrapani, Jaime Y. Kim
Publikováno v:
Cancer Res
To study the progression of bladder cancer from non–muscle-invasive to muscle-invasive disease, we have developed a novel toolkit that uses complementary approaches to achieve gene recombination in specific cell populations in the bladder urotheliu
Autor:
Douglas R. Spitz, Vishnu Menon, Kevin Cho, Michael C. Zahner, Yuting Wang, Naoshad Muhammad, Jin Zhang, Ramachandran Rashmi, Julie K. Schwarz, Xiaojing Huang, Buck E. Rogers, Gary J. Patti, Sisi Zhang, Yi Huang, Michael L. McCormick, Kay Jayachandran, Fiona Ruiz
Publikováno v:
Mol Cancer Ther
The purpose of this study was to determine if radiation (RT)-resistant cervical cancers are dependent upon glutamine metabolism driven by activation of the PI3K pathway and test whether PI3K pathway mutation predicts radiosensitization by inhibition
Autor:
Rebecca J. Nagy, Paul A. VanderLaan, Bryan C. Ulrich, Stephen Wang, Magda Bahcall, Giulia Costanza Leonardi, Emily S. Chambers, Man Xu, Marzia Capelletti, Jihyun Choi, Richard B. Lanman, Mark M. Awad, Amanda J. Redig, Hideo Baba, Paul Kirschmeier, Yu Imamura, Elena Ivanova, Frederick H. Wilson, Lynette M. Sholl, Cloud P. Paweletz, Masayuki Watanabe, Sangeetha Palakurthi, Pasi A. Jänne, Mizuki Nishino, Daniel B. Costa
Publikováno v:
Clinical Cancer Research. 24:5963-5976
Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquir
Autor:
Raghu Kalluri, Chanjuan Shi, Valerie M. Weaver, Anna Chytil, Harold L. Moses, Fei Ye, Philip Owens, Sergey V. Novitskiy, Michael W. Pickup, Agnieszka E. Gorska
Publikováno v:
Cancer immunology research, vol 5, iss 9
The survival rate for pancreatic ductal adenocarcinoma (PDAC) remains low. More therapeutic options to treat this disease are needed, for the current standard of care is ineffective. Using an animal model of aggressive PDAC (Kras/p48TGFβRIIKO), we d
Autor:
Atsuko Ogino, T. Kosaka, Marzia Capelletti, Jihyun Choi, Hideki Endoh, Junko Tanizaki, Michael J. Eck, Dalia Ercan, Magda Bahcall, Raymond M. Paranal, Geoffrey R. Oxnard, Pasi A. Jänne, Amanda J. Redig, Antonio Calles, Claire E. Repellin, Christine A. Lydon
Publikováno v:
Cancer Research. 77:2712-2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non–small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazo
Autor:
Aram F. Hezel, Nabeel Bardeesy, Cyril H. Benes, Jia-Chi Yeo, James T. Webber, Kevan M. Shokat, Travis Sullivan, Benjamin P. Kleinstiver, Roger L. Jenkins, Ultan McDermott, Yusuke Mizukami, Leah J. Damon, Regina K. Egan, Lei Shi, Supriya K. Saha, J. Keith Joung, John D. Gordan, Patricia Greninger, Rebecca S. Levin, Andrew S. Liss, Yasutaka Kato, Andrew X. Zhu, Kimberly M. Rieger-Christ, Mortada S. Najem, Lipika Goyal, Cristina R. Ferrone, Phuong Vu, Mathew J. Garnett
Publikováno v:
Cancer discovery, vol 6, iss 7
Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver bile duct malignancy exhibiting frequent isocitrate dehydrogenase (IDH1/IDH2) mutations. Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tr
Autor:
Yuwaraj Kadariya, Andres J. Klein-Szanto, Arti Shukla, Jacqueline Talarchek, Mitchell Cheung, Kathy Q. Cai, Melpo Christofidou-Solomidou, Joseph R. Testa, Craig W. Menges, Ralph A. Pietrofesa, Brooke T. Mossman
Publikováno v:
Cancer Prevention Research. 9:406-414
Exposure to asbestos is causally associated with the development of malignant mesothelioma, a cancer of cells lining the internal body cavities. Malignant mesothelioma is an aggressive cancer resistant to all current therapies. Once inhaled or ingest
Autor:
Thahir Farzan, Kimberly R. Kalli, Paul Haluska, Marc A. Becker, S. John Weroha, Tai W. Wong, Sean C. Harrington, James Krempski, Xiaonan Hou
Publikováno v:
Molecular Cancer Therapeutics. 12:2909-2916
Ovarian cancer mortality ranks highest among all gynecologic cancers with growth factor pathways playing an integral role in tumorigenesis, metastatic dissemination, and therapeutic resistance. The HER and VEGF receptor (VEGFR) are both overexpressed
Autor:
Alice C. Fan, Hua Fan-Minogue, Sanjiv S. Gambhir, Ramasamy Paulmurugan, Dean W. Felsher, Sandhya Bodapati, Tarik F. Massoud, David E. Solow-Cordero
Publikováno v:
Molecular Cancer Therapeutics. 12:1896-1905
Deregulation of c-Myc plays a central role in the tumorigenesis of many human cancers. Yet, the development of drugs regulating c-Myc activity has been challenging. To facilitate the identification of c-Myc inhibitors, we developed a molecular imagin
Autor:
Liqun Huang, Nengtai Ouyang, Basil Rigas, Gang Xie, Ka-Wing Cheng, Timothy S. Wiedmann, Ninche Alston, Gerardo G. Mackenzie, Chi Chun Wong
Publikováno v:
Molecular Cancer Therapeutics. 12:1417-1428
Phospho-sulindac is a sulindac derivative with promising anticancer activity in lung cancer, but its limited metabolic stability presents a major challenge for systemic therapy. We reasoned that inhalation delivery of phospho-sulindac might overcome